Bictegravir-emtricitabine-tenofovir alafenamide (BIC/FTC/TAF; Biktarvy, Gilead) is associated with faster CD4 cell count recovery and favorable virologic outcomes compared with other antiretroviral therapy (ART) among patients with advanced HIV infection, according to a recent study.
“The significance of this research lies in the fact that there is still a significant proportion of individuals who do not know they have HIV until it has ravaged their immune system,”